Trevi Therapeutics, Inc. Financing Cash Flow
Trevi Therapeutics, Inc. (TRVI) reported Financing Cash Flow of $164.58 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $164.36M, a 48.88% increase year-over-year.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $222.00K, a 97.45% decline year-over-year.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $284.00K, a 99.45% decline year-over-year.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.63M, a 67.28% decline year-over-year.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $121.01M, a 96.82% increase from fiscal 2024.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $61.48M.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was -$7.91M, a 107.11% decline from fiscal 2022.
- Trevi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $111.31M, a 435.77% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $164.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $164.58M 10-Q · filed 2026-08-06 | $164.86M derived: sum of 3 quarters · filed 2026-08-06 | $166.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $222.00K 10-Q · filed 2026-05-05 | $506.00K derived: sum of 2 quarters · filed 2026-05-05 | $2.13M derived: sum of 3 quarters · filed 2026-05-05 | $112.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $284.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $1.91M derived: sum of 2 quarters · filed 2026-03-17 | $112.31M derived: sum of 3 quarters · filed 2026-08-06 | $121.01M 10-K · filed 2026-03-17 |
| 2025-09-30 | $1.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $112.02M derived: sum of 2 quarters · filed 2026-08-06 | $120.73M 10-Q · filed 2025-11-13 | $172.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $110.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $119.10M 10-Q · filed 2026-08-06 | $170.57M derived: sum of 3 quarters · filed 2026-08-06 | $175.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $8.71M 10-Q · filed 2026-05-05 | $60.17M derived: sum of 2 quarters · filed 2026-05-05 | $65.15M derived: sum of 3 quarters · filed 2026-05-05 | $70.22M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $51.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $56.45M derived: sum of 2 quarters · filed 2026-03-17 | $61.51M derived: sum of 3 quarters · filed 2026-03-17 | $61.48M 10-K · filed 2026-03-17 |
| 2024-09-30 | $4.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $10.04M derived: sum of 2 quarters · filed 2025-11-13 | $10.02M 10-Q · filed 2025-11-13 | $9.96M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $5.04M 10-Q · filed 2025-08-07 | $4.99M derived: sum of 3 quarters · filed 2025-08-07 | $6.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$28.00K 10-Q · filed 2025-05-08 | -$82.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.43M derived: sum of 3 quarters · filed 2025-05-08 | -$6.24M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$54.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $1.46M derived: sum of 2 quarters · filed 2025-03-18 | -$6.21M derived: sum of 3 quarters · filed 2025-03-18 | -$7.91M 10-K · filed 2025-03-18 |
| 2023-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$6.15M derived: sum of 2 quarters · filed 2024-11-06 | -$7.86M 10-Q · filed 2024-11-06 | -$7.20M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$7.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$9.37M 10-Q · filed 2024-08-08 | -$8.71M derived: sum of 3 quarters · filed 2024-08-08 | $46.59M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.70M 10-Q · filed 2024-05-07 | -$1.05M derived: sum of 2 quarters · filed 2024-05-07 | $54.25M derived: sum of 3 quarters · filed 2024-05-07 | $110.23M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $652.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $55.95M derived: sum of 2 quarters · filed 2024-03-20 | $111.93M derived: sum of 3 quarters · filed 2024-03-20 | $111.31M 10-K · filed 2024-03-20 |
| 2022-09-30 | $55.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $111.28M derived: sum of 2 quarters · filed 2023-11-09 | $110.66M 10-Q · filed 2023-11-09 | $124.40M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $55.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $55.35M 10-Q · filed 2023-08-10 | $69.09M derived: sum of 3 quarters · filed 2023-08-10 | $69.23M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$625.00K 10-Q · filed 2023-05-11 | $13.12M derived: sum of 2 quarters · filed 2023-05-11 | $13.25M derived: sum of 3 quarters · filed 2023-05-11 | $16.00M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $13.88M derived: sum of 2 quarters · filed 2023-03-16 | $16.63M derived: sum of 3 quarters · filed 2023-03-16 | $20.77M 10-K · filed 2023-03-16 |
| 2021-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.89M derived: sum of 2 quarters · filed 2022-11-10 | $7.03M 10-Q · filed 2022-11-10 | $7.67M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $6.90M 10-Q · filed 2022-08-11 | $7.54M derived: sum of 3 quarters · filed 2022-08-11 | $23.63M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.15M 10-Q · filed 2022-05-12 | $4.78M derived: sum of 2 quarters · filed 2022-05-12 | $20.88M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $637.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $16.73M derived: sum of 2 quarters · filed 2022-03-17 | $16.72M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $16.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $16.08M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$12.00K 10-Q · filed 2021-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$138.00K derived: sum of 2 quarters · filed 2021-03-25 | $63.36M derived: sum of 3 quarters · filed 2021-03-25 | $73.21M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$138.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $63.36M derived: sum of 2 quarters · filed 2020-11-12 | $73.21M 10-Q · filed 2020-11-12 | $71.70M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $63.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $73.35M 10-Q · filed 2020-08-13 | $71.84M derived: sum of 3 quarters · filed 2020-08-13 | $82.31M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $9.85M 10-Q · filed 2020-05-07 | $8.34M derived: sum of 2 quarters · filed 2020-05-07 | $18.81M derived: sum of 3 quarters · filed 2020-05-07 | $15.53M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $8.96M derived: sum of 2 quarters · filed 2020-03-16 | $5.68M derived: sum of 3 quarters · filed 2020-03-16 | $3.63M 10-K · filed 2020-03-16 |
| 2018-09-30 | $10.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $7.19M derived: sum of 2 quarters · filed 2019-11-14 | $5.14M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | -$5.33M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$2.05M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |